We are very pleased to announce the award of a Small Business Innovation Research (SBIR) Phase I grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in support of our drug development program for Nonalcoholic Steatohepatitis (NASH), a dangerous liver disease. The funding will help us, along with our academic colleagues at UCLA, to proceed with preclinical testing of oxysterol-based drug candidate Oxy210, a novel anti-fibrotic agent with a unique pharmacological profile and mechanism of action. We are excited that this research could potentially provide improved treatment options to patients with liver disease such as NASH.